Now Playing
Opinion|Videos|May 12, 2025
An Overview of the ARANOTE Trial
Author(s)Neal Shore, MD, FACS
A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of the study design and topline results.
Advertisement
Episodes in this series
Advanced Prostate Cancer Treatment Strategies
Panel Introduction
Featured Expert:
- Neal D. Shore, MD, FACS: Medical oncologist and urologist at Carolina Urologic Research Center, Myrtle Beach, South Carolina. Dr Shore is a recognized researcher in urologic oncology with expertise in clinical trials for advanced prostate cancer treatments.
Expert Specialty Areas
- Urologic oncology
- Clinical research in metastatic hormone-sensitive prostate cancer (mHSPC)
- Novel androgen receptor pathway inhibitors
- Prostate-specific antigen response as predictive biomarker
ARANOTE Trial Overview
Key Themes:
- Phase 3 clinical trial evaluating darolutamide plus ADT in patients with mHSPC
- Trial design and methodology
- Significant efficacy outcomes
Expert Insights:
- Dr Shore provided an overview of the ARANOTE trial design, which evaluated darolutamide in combination with androgen deprivation therapy (ADT) for patients with mHSPC.
- The discussion highlighted the topline results demonstrating clinical benefit with this treatment approach.
Advertisement
Related to this article
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.
A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.
Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
2
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
3
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5